Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA
Autor(es): Kuijf Mark L,van Doorn Pieter A,Tio-Gillen Anne P,Geleijns Karin,Ang C Wim,Hooijkaas Herbert,Hop Wim C J,Jacobs Bart C
Resumo: The Inflammatory Neuropathy and Treatment (INCAT) group developed a standardized ELISA method for the detection of serum anti-GM1 antibodies. The diagnostic value of anti-GM1 antibodies determined by this method has not yet been established in large groups of patients. We assessed the reproducibility, sources of variation, optimal cut-off values and evaluated the diagnostic relevance of the INCAT-ELISA in various groups of patients and controls (N=1232). The coefficient of variance was 11.2% for IgM and 3.8% for IgG. High IgG titers were only found in Guillain-Barré syndrome (GBS) and other inflammatory polyneuropathies. High IgM titers were associated with GBS and multifocal motor neuropathy. Low IgM titers had no additional diagnostic value. The INCAT-ELISA is a reliable test with additional diagnostic value in specific clinical situations.
Palavras-Chave: Inflammatory Neuropathy and Treatment group (INCAT); ELISA; GM1 ganglioside; Peripheral neuropathy; Diagnosis; Autoantibodies
Imprenta: Journal of the Neurological Sciences, v. 239, n. 1, p. 37-44, 2005
Identificador do objeto digital: 10.1016/j.jns.2005.07.009
Descritores: Guillain-Barre Syndrome - Cytopathology ; Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Serology ; Guillain-Barre Syndrome - Immunology ; Guillain-Barre Syndrome - Public health
Data de publicação: 2005
